Columbamine (Protoberberine Alkaloid · Anti-inflammatory · Antimicrobial)
| Compound | Columbamine |
| Chemical class | Alkaloid — Isoquinoline (Protoberberine; 2-Demethylberberine) |
| CAS | 3621-36-1 |
| Primary source | Berberis spp. (barberry), Coptis spp., Hydrastis canadensis |
| Key applications | Anti-inflammatory, antimicrobial, antioxidant, berberine analogue |
| Claim strength | Moderate |
| Typical form | Berberis alkaloid extract co-constituent; minor protoberberine |
| Buy from Herbuno | Contact Herbuno for sourcing enquiries → |
Commercial source: Columbamine is commercially available as a minor co-constituent of Berberis and Coptis alkaloid extracts, where berberine is the dominant alkaloid and columbamine constitutes approximately 1–5% of total alkaloid content. Isolated columbamine is available from specialist chemical suppliers. See sourcing options below. Traditional use: As a constituent of barberry and Coptis preparations, columbamine participates in these herbs’ traditional anti-infective, digestive, and anti-inflammatory applications. It was historically isolated from Columba plant preparations (a South American vine) but its pharmacological research primarily uses Berberis sources. Research trajectory: Columbamine has a limited but growing research profile for anti-inflammatory (NF-κB inhibition), antimicrobial, neuroprotective (MAO inhibition), and antioxidant activities. It is primarily studied as a berberine structural analogue to establish structure-activity relationships across the protoberberine class. See sourcing options below.
Evidence for Columbamine Applications
Anti-inflammatory and antioxidant: Columbamine inhibits NF-κB and reduces COX-2 and TNF-α in macrophage models. Antioxidant activity is documented via DPPH and ABTS assays with potency comparable to berberine. The structural difference (columbamine lacks the methylenedioxy ring of berberine, having an additional free methoxy group) results in somewhat different enzyme affinity profiles. Claim strength: Moderate.
Antimicrobial: Columbamine inhibits bacterial growth via mechanisms shared with berberine (DNA gyrase inhibition) but with slightly different activity spectra across bacterial species. Anti-biofilm activity is documented. Contributes to the overall antimicrobial activity of Berberis and Coptis extracts. Claim strength: Moderate.
MAO inhibition and neuroprotective: Columbamine has mild MAO-A inhibitory activity — more pronounced than berberine — which is relevant to antidepressant and neuroprotective research contexts. This distinguishes it from berberine’s primarily metabolic activity profile. Claim strength: Emerging.
Browse Standardised Extract Powders →
Dosage & Formulator Specification
Columbamine is not formulated as a standalone supplement. In Berberis aristata extract standardised to berberine content, columbamine constitutes approximately 1–5% of total alkaloids. Standard berberine extract at 500 mg/day delivers approximately 5–25 mg columbamine as a co-active. Isolated columbamine is available from specialist chemical suppliers for research formulation contexts.
The practical formulation implication of columbamine is that berberine extracts specified from whole Berberis or Coptis plant material (rather than isolated berberine HCl) deliver the full protoberberine alkaloid complex including columbamine. This provides the “alkaloid synergy” argument for botanical extract over pure berberine isolate.
Frequently Asked Questions — Columbamine
What is the structural difference between columbamine and berberine?
Berberine has a methylenedioxy group at positions 9 and 10 (the D-ring). Columbamine has two separate methoxy groups at positions 9 and 10 (i.e., the oxygen bridge forming the methylenedioxy ring is absent, replaced by two independent methoxy groups). This small structural difference alters electron distribution, receptor binding affinity, and metabolic handling. Columbamine is sometimes called “2-demethylcolumbamine” in older nomenclature but is more accurately described as “9,10-dimethoxyberberine without the C2-C3 methylenedioxy bridge.”
Is columbamine relevant to the blood glucose-lowering effect of Berberis extract?
Columbamine has some AMPK-activating activity in cell models, paralleling berberine, but its contribution to whole Berberis extract glycaemic effects is minor given its low proportion of total alkaloids. The blood glucose evidence for berberine-standardised extracts is attributable primarily to berberine, with columbamine as a minor co-active providing additive rather than primary contribution.
Could columbamine’s MAO inhibition cause problems in supplement formulations?
Columbamine’s MAO-A inhibition is mild and present at concentrations far below therapeutic MAO-inhibitor doses. At typical supplement exposure from Berberis extract (where columbamine is <5% of total alkaloids), clinically significant MAO inhibition is not expected. Standard advisory language for individuals on antidepressants is appropriate as a precaution given the MAO interaction potential of the alkaloid class collectively.
Should I specify “total alkaloids” or “berberine content” when sourcing Berberis extract?
For precise berberine dosing, specify berberine content by HPLC. For the full protoberberine alkaloid complex including columbamine, palmatine, and other minor alkaloids, specify “total alkaloids” or “total protoberberines” by HPLC with individual alkaloid profile reported on CoA. Premium formulations documenting full alkaloid complexity should request both total and individual alkaloid quantification.
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery